Svb Leerink reissued their outperform rating on shares of CryoPort (NASDAQ:CYRX) in a report issued on Monday morning, Zacks.com reports. Svb Leerink also issued estimates for CryoPort’s Q2 2019 earnings at ($0.07) EPS, Q3 2019 earnings at ($0.06) EPS, Q4 2019 earnings at ($0.07) EPS, FY2019 earnings at ($0.29) EPS, Q1 2020 earnings at ($0.03) EPS, Q2 2020 earnings at ($0.03) EPS, Q3 2020 earnings at ($0.03) EPS, Q4 2020 earnings at ($0.03) EPS, FY2020 earnings at ($0.10) EPS, FY2021 earnings at ($0.05) EPS and FY2022 earnings at $0.21 EPS.

Several other analysts have also commented on the stock. BidaskClub raised shares of Zebra Technologies from a hold rating to a buy rating in a research report on Saturday, July 6th. Needham & Company LLC reaffirmed a buy rating and set a $40.00 price target on shares of ACADIA Pharmaceuticals in a research report on Monday, July 1st. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of Buy and a consensus price target of $21.00.

CYRX stock opened at $19.38 on Monday. The stock has a market cap of $610.33 million, a price-to-earnings ratio of -62.52 and a beta of 0.85. The company has a current ratio of 11.57, a quick ratio of 11.52 and a debt-to-equity ratio of 0.42. The firm’s 50 day moving average price is $18.40. CryoPort has a one year low of $8.28 and a one year high of $20.79.

CryoPort (NASDAQ:CYRX) last released its quarterly earnings results on Thursday, May 2nd. The consumer goods maker reported ($0.08) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.08). The firm had revenue of $6.65 million for the quarter, compared to analyst estimates of $6.56 million. CryoPort had a negative net margin of 41.61% and a negative return on equity of 28.30%. The business’s revenue for the quarter was up 65.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.10) EPS. On average, sell-side analysts forecast that CryoPort will post -0.29 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently made changes to their positions in the business. BNP Paribas Arbitrage SA purchased a new stake in CryoPort in the first quarter valued at approximately $74,000. Metropolitan Life Insurance Co. NY raised its position in CryoPort by 356.6% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 8,607 shares of the consumer goods maker’s stock valued at $95,000 after purchasing an additional 6,722 shares during the period. MML Investors Services LLC purchased a new stake in CryoPort in the fourth quarter valued at approximately $157,000. Bank of America Corp DE raised its position in CryoPort by 92.3% in the fourth quarter. Bank of America Corp DE now owns 16,037 shares of the consumer goods maker’s stock valued at $176,000 after purchasing an additional 7,697 shares during the period. Finally, Conestoga Capital Advisors LLC purchased a new stake in CryoPort in the first quarter valued at approximately $355,000. 53.54% of the stock is currently owned by institutional investors.

CryoPort Company Profile

CryoPort, Inc engages in the provision of logistics solutions to the life science industry. It also provides logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide, including points-of-care, clinical research organizations central laboratories, biopharmaceuticals, contract manufacturing, health centers, and university researchers.

Read More: Moving Average – How it Helps Investors in Stock Selection

Analyst Recommendations for CryoPort (NASDAQ:CYRX)

Receive News & Ratings for CryoPort Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoPort and related companies with MarketBeat.com's FREE daily email newsletter.